SAB BIOTHERAPEUTICS, INC. Finance Lease, Liability, to be Paid, after Year Five
SAB BIOTHERAPEUTICS, INC. (SABS) had Finance Lease, Liability, to be Paid, after Year Five of $3.18 million as of 2025-12-31, per its 10-K filed 2026-03-09.
Financial Statements › Notes › Commitment and Contingencies › Finance Lease, Liability, to be Paid, Fiscal Year Maturity
us-gaap:FinanceLeaseLiabilityPaymentsDueAfterYearFive · last filed 2026-03-09
- 2025-12-31: Finance Lease, Liability, to be Paid, after Year Five $3.18M.
- 2024-12-31: Finance Lease, Liability, to be Paid, after Year Five $3.58M.
- 2023-12-31: Finance Lease, Liability, to be Paid, after Year Five $3.98M.
- 2023-06-30: Finance Lease, Liability, to be Paid, after Year Five $4.38M.
| Period end | Finance Lease, Liability, to be Paid, after Year Five |
|---|---|
| 2025-12-31 | $3.18M 10-K · filed 2026-03-09 |
| 2024-12-31 | $3.58M 10-K · filed 2025-03-31 |
| 2023-12-31 | $3.98M 10-K · filed 2024-03-29 |
| 2023-06-30 | $4.38M 10-Q · filed 2023-08-21 |
| 2023-03-31 | $4.38M 10-Q · filed 2023-05-15 |
| 2022-12-31 | $4.38M 10-K · filed 2023-04-14 |
| 2021-12-31 | $4.78M 10-K/A · filed 2023-04-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |